X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Brimochol™ PF (combination of carbachol and brimonidine tartrate) is a preservative-free topical ophthalmic solution which is used to lower pressure in the eyes, it is being investigated for the treatment of presbyopia.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
Brimochol™ PF (combination of carbachol and brimonidine tartrate) is a preservative-free topical ophthalmic solution which is used to lower pressure in the eyes, it is being investigated for the treatment of presbyopia.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
Under the terms of the agreement, ZKO will be responsible for clinical development and regulatory approval for BRIMOCHOL PF and Carbachol PF in the specified territories, and subsequently the commercialization activities for the products.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zhaoke Ophthalmology
Deal Size: $130.0 million Upfront Cash: $15.0 million
Deal Type: Licensing Agreement May 11, 2022
Details:
Non-clinical work with BRIMOCHOL PF demonstrating additive effects of brimonidine on the pharmacokinetics and pharmacodynamics of carbachol proved predictive of our clinical results showing contribution of elements in our Phase 2 study.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
Results from Phase 2 trial, demonstrate that BRIMOCHOL, a fixed-dose combination of carbachol (a cholinergic miotic agent) and brimonidine tartrate (an alpha-2 agonist), is a safe and effective once-daily eye drop to correct the loss of near vision associated with presbyopia.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
Proceeds will support clinical and commercial efforts for lead asset BRIMOCHOL™ under investigation for presbyopia as well as new research and development activities in the Company’s drug development pipeline.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: LSP
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 10, 2021
Details:
The Phase 2 clinical trial is a double-masked, randomized crossover study designed to evaluate the safety and efficacy of two proprietary formulations of BRIMOCHOL topical ophthalmic solution in patients with emmetropic phakic and pseudophakic presbyopia.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2021
Details:
Proceeds from the Series A financing will be used to advance the clinical development program for the company’s lead asset, BRIMOCHOL™, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: BRIMOCHOL
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: $36.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
